Search
Filter Results
Displaying 61–70 of 1043 results
-
Oct 30, 2024
BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
The Foundation funded Dr. David Gamm for development of the induced pluripotent stem cell approach to be used in the trial.
-
General thank you message for registering for an upcoming event.
-
Oct 29, 2024
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
The 36-participant trial will take place at multiple sites in Australia.
-
Oct 25, 2024
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
-
Oct 25, 2024
Eye on the Cure Podcast | Episode 75: Sharon King
Sharon King, co-founder and president of Taylor’s Tale, talks to host Ben Shaberman about her family’s journey when her daughter Taylor was diagnosed with Batten disease.
-
Ongoing Foundation Fighting Blindness national webinars around the latest research for blinding diseases.
-
Oct 23, 2024
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
Merger will provide additional capital for gene therapy development.
-
The Foundation’s grants and awards are critical and allow recipients to secure additional and often larger awards from other funding entities like the National Institute of Health.
-
Over the next five years, our focus is to raise awareness of our science initiatives, both within and outside the Foundation, particularly around our research portfolio.
-
To make a bigger impact on our mission to turn early research into clinical trials for people with IRDs and dry AMD, the Foundation will grow its network of collaborators and partners.